Related Experiment Video
Updated: May 31, 2026
09:34
Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
Published on: April 4, 2018
Association between microRNA 155 gene polymorphism and sporadic Parkinson's disease
Siwei Luo1, Jinrong Li2, Yu Zhang3
1Department of Neurology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China.
Personalized Medicine
|May 29, 2026
Summary
The miR-155 rs767649 A allele may protect against Parkinson's disease (PD). Elevated serum miR-155 levels correlate with PD severity and could serve as a diagnostic biomarker.
Area of Science:
- Genetics
- Neuroscience
- Biomarkers
Background:
- The single nucleotide polymorphism (SNP) rs767649 in the miR-155 gene is implicated in neurological disorders.
- Its association with sporadic Parkinson's disease (PD) requires further investigation.
Purpose of the Study:
- To investigate the association between the miR-155 rs767649 polymorphism and PD risk.
- To evaluate the correlation between serum miR-155 levels, PD severity, and cognitive function.
Main Methods:
- Genotyping of rs767649 SNP using TaqMan assay.
- Quantification of serum miR-155 levels via RT-qPCR.
- Statistical analyses including ROC, Pearson correlation, and logistic regression.
Main Results:
- The A allele of rs767649 was found to be protective against PD in the Han Chinese population.
- The TT genotype was linked to higher serum miR-155, increased motor impairment, and reduced cognitive function in PD patients.
- Elevated serum miR-155 levels correlated with PD severity and were identified as an independent risk factor.
Conclusions:
- The miR-155 rs767649 polymorphism may influence PD susceptibility, with the A allele offering potential protection.
- Elevated serum miR-155 levels are associated with PD progression and may serve as a potential diagnostic biomarker.
Related Concept Videos
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:05Single Nucleotide Polymorphisms-SNPs
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...